Applied Therapeutics (APLT)
(Real Time Quote from BATS)
$4.35 USD
+0.07 (1.64%)
Updated Apr 29, 2024 11:50 AM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Applied Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 10 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 10 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 75 | 83 | 106 | 94 | 46 |
Income After Depreciation & Amortization | -65 | -83 | -106 | -94 | -46 |
Non-Operating Income | -55 | 0 | 0 | 1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -120 | -83 | -106 | -94 | -46 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -120 | -83 | -106 | -94 | -46 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -120 | -83 | -106 | -94 | -46 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -62 | -79 | -101 | -92 | -46 |
Depreciation & Amortization (Cash Flow) | 2 | 4 | 5 | 3 | 0 |
Income After Depreciation & Amortization | -65 | -83 | -106 | -94 | -46 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 84.25 | 37.83 | 25.60 | 21.97 | 12.83 |
Diluted EPS Before Non-Recurring Items | -1.42 | -2.06 | -4.12 | -4.28 | -3.55 |
Diluted Net EPS (GAAP) | -1.42 | -2.18 | -4.12 | -4.28 | -3.55 |
Fiscal Year end for Applied Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | -0.67 | 0.00 | 0.00 | 10.66 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | -0.67 | 0.00 | 0.00 | 10.66 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 20.34 | 15.50 | 17.17 | 21.52 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -21.01 | -15.50 | -17.17 | -10.86 |
Non-Operating Income | NA | -16.67 | -26.88 | -12.40 | 0.72 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -37.68 | -42.37 | -29.58 | -10.14 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -37.68 | -42.37 | -29.58 | -10.14 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -37.68 | -42.37 | -29.58 | -10.14 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 84.25 | 90.67 | 79.04 | 56.36 |
Diluted EPS Before Non-Recurring Items | NA | -0.33 | -0.47 | -0.37 | -0.18 |
Diluted Net EPS (GAAP) | NA | -0.40 | -0.47 | -0.37 | -0.18 |